4//SEC Filing
ARCH Venture Fund VIII, L.P. 4
Accession 0000899243-20-028809
CIK 0001659352other
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 8:07 PM ET
Size
37.9 KB
Accession
0000899243-20-028809
Insider Transaction Report
Form 4
ARCH Venture Fund VIII, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-10-16+420,368→ 2,268,903 total(indirect: See Footnote) - Conversion
Series A Preferred Stock
2020-10-16−6,500,000→ 0 total(indirect: See Footnote)→ Common Stock (831,521 underlying) - Conversion
Series B Preferred Stock
2020-10-16−2,333,333→ 0 total(indirect: See Footnote)→ Common Stock (326,953 underlying) - Conversion
Common Stock
2020-10-16+326,953→ 1,158,474 total(indirect: See Footnote) - Purchase
Common Stock
2020-10-16$15.00/sh+235,000$3,525,000→ 2,503,903 total(indirect: See Footnote) - Conversion
Series C Preferred Stock
2020-10-16−1,320,097→ 0 total(indirect: See Footnote)→ Common Stock (191,721 underlying) - Conversion
Common Stock
2020-10-16+1,784,572→ 1,848,535 total(indirect: See Footnote) - Conversion
Common Stock
2020-10-16+191,721→ 1,350,195 total(indirect: See Footnote) - Conversion
Series B Preferred Stock
2020-10-16−3,000,000→ 0 total(indirect: See Footnote)→ Common Stock (420,368 underlying) - Conversion
Series A Preferred Stock
2020-10-16−13,950,000→ 0 total(indirect: See Footnote)→ Common Stock (1,784,572 underlying) - Conversion
Common Stock
2020-10-16+831,521→ 831,521 total(indirect: See Footnote)
Footnotes (5)
- [F1]Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.8170 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date.
- [F2]Shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F3]Shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F4]Each share of Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.1366 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
- [F5]Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-6.8855 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Documents
Issuer
Codiak BioSciences, Inc.
CIK 0001659352
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001605598
Filing Metadata
- Form type
- 4
- Filed
- Oct 19, 8:00 PM ET
- Accepted
- Oct 20, 8:07 PM ET
- Size
- 37.9 KB